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Abstract
Objective: Neuroinflammation is an important pathogenic mechanism in amy-
otrophic lateral sclerosis (ALS), with regulatory T cells (Tregs) mediating a slower
rate of disease progression. Dimethyl fumarate enhances Treg levels and suppresses
pro-inflammatory T cells. The present study assessed the safety and efficacy of
dimethyl fumarate in ALS. Methods: Phase-2, double-blind, placebo-controlled
randomised clinical trial recruited participants from May 1, 2018 to September 25,
2019, across six Australian sites. Participants were randomised (2:1 ratio) to
dimethyl fumarate (480 mg/day) or matching placebo, completing visits at screen-
ing, baseline, weeks 12, 24 and 36. The primary efficacy endpoint was a change in
Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) at
week 36. Secondary outcome measures included survival, neurophysiological index
(NI), respiratory function, urinary neurotrophin-receptor p75 and quality of life.
Results: A total of 107 participants were randomised to dimethyl fumarate
(n = 72) or placebo (n = 35). ALSFRS-R score was not significantly different at
week 36 (1.12 [3.75 to 1.52, p = 0.41]). Dimethyl fumarate was associated with
a reduced NI decline week 36 (differences in the least-squares mean: (0.84 [0.51
to 2.22, p = 0.22]). There were no significant differences in other secondary out-
come measures. Safety profiles were comparable between groups. Interpretation:
Dimethyl fumarate, in combination with riluzole, was safe and well-tolerated in
ALS. There was no significant improvement in the primary endpoint. The trial pro-
vides class I evidence for safety and lack of efficacy of dimethyl fumarate in ALS.
Introduction
Amyotrophic lateral sclerosis (ALS) is a rapidly progres-
sive neurodegenerative disorder of the human motor sys-
tem, with a mean survival of 3–5 years.1,2 At a
pathophysiological level, ALS is a multistep process,
mediated through complex interactions of genetic, epige-
netic, and environmental factors.2–5 At present, riluzole
(an anti-glutamatergic agent) and edaravone (a free radi-
cal scavenger that reduces oxidative stress) are clinically
available for the treatment of ALS, and both exert modest
benefits.6–8 More recently, masitinib (a microglial agent)9
and sodium phenylbutyrate (PB) and tauroursodeoxy-
cholic acid (TUDCA) [AMX 035]10 have also shown
modest effects in patients with rapidly progressive ALS,
although these agents are not clinically available.
Neuroinflammation has emerged as a potential mecha-
nism contributing to ALS pathophysiology, with infiltrating
T lymphocytes leading to immune dysregulation and neu-
ronal degeneration.11,12 Studies using transgenic mutant
SOD1 mice (mSOD1) identified the presence of anti-
inflammatory cytokines in the early stages of ALS, mediated
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through central nervous system microglia and astrocytes,
whereas an increase in pro-inflammatory mediators was
observed in the rapid phase of disease progression.13–16
The early stages of ALS are marked by an upregulation
of regulatory T cells (Tregs) and increased levels of the
neuroprotective type 2 microglia (M2) phenotype.12,16
Together, Tregs and M2 macrophages increase the levels
of anti-inflammatory cytokines, such as interleukin (IL)-
4, IL-10 and transforming growth factor b; suppress the
pro-inflammatory helper-T (Th1) cells and Th17 lympho-
cytes; and suppress the activation/expansion of
CD4+CD25 effector T lymphocytes.17
Disease progression is associated with conversion to a
neurotoxic inflammatory response dominated by type 1
microglia (M1) and dysfunctional Tregs, which can no
longer suppress Th1 and Th17 lymphocytes, as well as
increased levels of pro-inflammatory cytokines (IL-1b, IL-
6, interferon [IFN]-c and tumour necrosis factor a).11,12
A correlation between Tregs and the rate of disease pro-
gression has been previously established in ALS and was
associated with neuroprotective and neurodegenerative
effects in ALS mouse models and some clinical trials,16,18
although other clinical trials have not reported a clinic
benefit despite an increase in percentage of Tregs.19
Importantly, the loss of Tregs’ suppressive ability in
patients with ALS was reported to be transient, and the
ability was regained when they were expanded in a differ-
ent environment.17,20 This was corroborated by studies
demonstrating that passive infusions of expanded Tregs
had a suppressive function and slowed disease progression
in patients with sporadic ALS.21 Collectively, these results
highlight Tregs as a potential novel therapeutic target for
the treatment of ALS.
Dimethyl fumarate, an FDA-approved medication used
for the treatment of relapsing-remitting multiple sclero-
sis,22,23 has been shown to alter immune response towards
more anti-inflammatory subsets. Specifically, dimethyl
fumarate increased the number of anti-inflammatory
CCR3+Th2 and Treg cells, shifting the pro- to anti-
inflammatory ratio (Th2/Th1Th17 and Treg/Th1Th17),
with a simultaneous reduction in pro-inflammatory T
cells (CD4+IFN-c; CD8+IFN-c), thus highlighting its
potential as a neuroprotective agent.17–19 As such, the
objective of this phase 2, randomised, placebo-controlled,
multicentric, double-blind study was to assess the efficacy
and safety of dimethyl fumarate in patients with ALS.
Methods
Study design and participants
This phase 2 study was conducted at six academic medi-
cal centres, coordinated through ALS Trials Australia. The
study duration was 42 weeks: 14 days of screening; a 36-
week treatment period; and 4-week follow-up period. The
study was approved by the Human Research Ethics Com-
mittee and Research Governance Office at the lead site
(Westmead Hospital; ethics number: HREC/17/WMEAD/
353). The study was conducted in accordance with the
Declaration of Helsinki and Good Clinical Practice guide-
lines. Participants provided written informed consent
before the study began. The study protocol was pub-
lished.24
Men and women aged 18–85 years (inclusive) with a
diagnosis of possible, probable, or definite sporadic ALS,
per the Awaji criteria,25 and using standard clinical assess-
ment criteria were enrolled in the study. Patients were
deemed eligible if their disease duration was <24 months
at the time of enrolment, they had had magnetic reso-
nance imaging scans of the brain or spinal cord taken
within 2 years prior to screening to exclude alternative
disease processes, and they had a forced vital capacity
(FVC) of >60% of predicted value adjusted for sex, age,
and height. Eligible patients were allowed to use riluzole
if they had been on a stable dose for ≥30 days prior to
the screening visit.
The key exclusion criteria were: mechanical ventilation
dependency; participation in other clinical trials; exposure
to an investigational drug (within 12 weeks prior to
screening); taking immunosuppressive medications; pres-
ence of a feeding tube at screening; familial history of
ALS as reported by participant (separate genetic testing
was not undertaken); active infectious disease (including
hepatitis B or C, tuberculosis, or human immunodefi-
ciency virus); unstable psychiatric or medical conditions;
and clinically significant abnormal safety laboratory val-
ues. Women of childbearing potential were required to
use medically acceptable contraception during the study.
Pregnant or lactating women were excluded from the
study.
Randomisation and masking
At screening, eligible patients were randomised 2:1 to
receive either dimethyl fumarate or placebo. A computer-
aided interactive web response system with random num-
ber generation was used, and this provided the patient
medication kit/bottle number(s) of the blinded investiga-
tional product to be dispensed. All randomisation proce-
dures were managed by a third-party vendor (Cenduit,
India). The investigational product and placebo tablets
were identical in physical appearance (matched in size,
colour, presentation, and taste). All the patients and per-
sonnel at all the participating sites were blinded to the
treatment assignments. Dimethyl fumarate was provided
to the participating sites by Biogen Idec Australia via a
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central supplier and dispensed by the clinical study phar-
macist or equivalent at each site.
Procedures
Dimethyl fumarate was administered at a dose of 240 mg
twice daily through to week 36. Patients in the placebo
group received matching capsules orally twice daily.
Eligible patients underwent a 14-day screening period.
All the baseline characteristics were assessed at week 0.
The neurological and physical examinations were per-
formed at Weeks 12, 24, 36, and 40. Scores for the
Revised Amyotrophic Lateral Sclerosis Functional Rating
Scale (ALSFRS-R),26 the neurophysiological index (NI),
the split-hand index (SI), the FVC, the sniff nasal
inspiratory pressure (SNIP), and the Medical Research
Council (MRC), along with urine neurotrophin-receptor
p75 levels, were assessed at all timepoints. The revised
ALS-specific QoL (ALSSQoL-R) score was assessed at
Weeks 12, 36, and 40. Survival status was assessed at
week 36.
Haematological and biochemical laboratory evaluations
and adverse events were recorded throughout the study
duration. An independent data safety management board
reviewed the safety aspects and monitored the outcome of
the study (Chair Professor David Brown, Professor
Domini Dwyer and Professor Golo Ahlenstiel).
Outcomes
The primary endpoint was the change in the ALSFRS-R
total score at 36 weeks. The ALSFRS-R score assesses the
rate of disease progression based on four major func-
tional domains: bulbar function (speech, swallowing,
salivation); fine motor tasks (cutting, handling utensils,
dressing and hygiene); gross motor tasks (walking and
climbing stairs) and respiratory function (dyspnoea and
orthopnoea).
Secondary endpoints included survival (in months),
defined as the time from symptom onset to death or tra-
cheostomy, lower motor neuron dysfunction (as assessed
by MRC, NI and SI scores); respiratory dysfunction (FVC
(%) and SNIP); urinary levels of neurotrophin-receptor
p75 (biomarker for ALS)27 and quality of life (ALSSQoL-
R score). While in the original protocol primary and sec-
ondary endpoints were to be analysed at week 40, given
that treatment ended at week 36, all efficacy endpoints
were re-analysed at week 36. The protocol amendment
was finalised after statistical planning, but prior to break-
ing the blind. This was documented and approved by the
relevant ethics committee(s). Safety assessments included,
adverse events, serious adverse events, clinical laboratory
values (haematology, biochemistry and urinalysis), vital
sign measurements and physical examination. ALS disease
progression was not considered to be an adverse event.
Statistical analysis
Based on previous clinical experience, it was assumed that
the mean difference in the ALSFRS-R between active and
control groups was 7 (with SD of 8%) at 36 weeks. A
clinically important response rate on Tecfidera was
defined as 0.9. Given a 2:1 (dimethyl fumarate: placebo)
allocation, 90% power and 5% statistical significance rate,
it was estimated that a total of 72 (dimethyl fumarate, 48:
placebo, 24) evaluable participants would need to be
recruited for the study.
Statistical analyses were performed using SAS software
version 9.4 (Cary, NC, USA). For continuous variables,
results were presented as the number of contributing
observations (n), mean, SD, median, minimum, and max-
imum. The number and percentage for each category
were presented in the summary of categorical variables.
The change from baseline at week 36 was calculated for
all parameters (except survival) and the between-
treatment difference was analysed using one-sided p-
values at 5% significance level and 95% confidence inter-
vals. Survival analysis was performed using a Kaplan–
Meier curve. Multiple imputation (MI) method was used
for missing data. A statistically significant result was
regarded as a p < 0.05. This study is registered with Aus-
tralia and New Zealand Clinical Trial Registry, number
ACTRN12618000534280 (Date submitted 5/04/2018, 1st
patient recruited 1 May 2018).
Results
Between 1 May 2018 and 25 September 2019, 117 partici-
pants were screened and 109 were enrolled on the TEALS
study. Of these, 107 participants were randomised to
receive either dimethyl fumarate or placebo in a ratio of
2:1 ratio. In total, 70% of participants (n = 75) com-
pleted the study, with discontinuation rates being similar
for dimethyl fumarate (N = 50, 30.6%) and placebo
(N = 25, 28.6%) cohorts (Fig. 1). Although 56% of drop-
out patients occurred between weeks 12–24 (59% tec-
fidera; 41% placebo), and 44% between weeks 24–36
(60% tecfidera; 40% placebo), the study was adequately
powered to detect the prespecified difference in the pri-
mary endpoint between dimethyl fumarate and placebo.
The median treatment duration was 24.1 weeks, with the
majority of participants being male (65.4%) and Cau-
casian (88.8%). The mean age of participants at recruit-
ment was 6010.2 years. The demographic and baseline
characteristics were comparable between the dimethyl
fumarate and placebo groups (Table 1).
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Efficacy
Primary endpoint
The primary endpoint was the change in ALSFRS-R
score at week 36. As explained in the methods, in the
original protocol primary and secondary endpoints were
to be analysed at week 40, however, given that treatment
ended at week 36, all efficacy endpoints were analysed at
week 36. There were no significant difference in the
ALSFRS-R score between the dimethyl fumarate and
placebo groups at week 36. Specifically, the between-
group least-squares mean difference (ΔLSM) was 1.12
(3.75 to 1.52, p = 0.41, Table 2, Fig. 2) at week 36.
Data imputation (using the MI method) was undertaken
in 24 participants (22.4%), 16 in the dimethyl fumarate
(22.2%) group and 8 (22.9%) in placebo group. The
ALSFRS-R was imputed from week 12 in 13.1% of par-
ticipants (9.7% dimethyl fumarate, 20% placebo) and

































Figure 1. Trial profile. *Two patients were not randomised: one patient did not wish to continue; one patient experienced cardiomyopathy.
†Reasons for discontinuation in the dimethyl fumarate group: one patient died; four patients were unable to swallow the investigational product;
five patients were too unwell to continue the trial (one patient each experienced abdominal bloating and cramping; unmanageable motor neuron
symptoms, and disease progression; in two patients, the reason was not known); three patients were too unwell to travel to the clinic because of
progression of amyotrophic lateral sclerosis; two compliance failures; six consent withdrawals and one patient was unwilling to continue the trial
due to adverse events. ‡Reasons for discontinuations in the placebo group: three patients withdrew because of progression of amyotrophic lateral
sclerosis; three patients were unwilling to continue the trial; two patients withdrew due to poor health; one patient was unable to swallow the
investigational product and one patient discontinued due to progression of ALS.
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Secondary endpoints
Dimethyl fumarate exerted a significant effect on the neu-
rophysiological index score, a robust neurophysiological
biomarker of disease progression in ALS.28,29 The rate of
decline in NI was reduced in the dimethyl fumarate
group, with the ΔLSM 0.84 (0.51 to 2.22, p = 0.22;
Table 2), although this difference was not significant.
Data imputation was undertaken in 30 participants
(28%), 18 in the dimethyl fumarate (25%) group and 12
(34%) in the placebo group. The NI was imputed from





(n = 35) (n = 72)
Age, mean (SD), years 58.7 (11.0) 60.1 (9.8)
Sex n (%)
Male 23 (66) 47 (65)
Female 12 (34) 25 (35)
Race, n (%)
White 31 (89) 64 (89)
Asian 2 (6) 3 (4)
Other 2 (6) 4 (6)
Smoking status
Smokers, n (%) 4 (11) 9 (13)
Number of cigarettes
per day, mean (SD)
16.3 (9.5) 9.0 (5.7)
Diagnosis duration, mean (SD), days 201.6 (165.5) 242.5 (194.9)
Disease onset type, n (%)
Bulbar 4 (11) 13 (18)
Limb 30 (86) 59 (82)
Both 1 (3) 0
ALS diagnosis, n (%)
Definite 12 (34) 17 (24)
Probable 15 (43) 39 (54)
Possible 8 (23) 16 (22)
ALSFRS-R total score, mean (SD) 38.7 (4.5) 38.6 (5.5)5
Rate of disease progression/month 2.2 (2.3) 2.1 (1.8)
NI, mean (SD)2 2.6 (4.5) 2.5 (5.4)
SI, mean (SD)2 4.0 (4.2) 3.9 (3.7)
MRC score, mean (SD)3 129.1 (17.9) 127.5 (16.7)
%FVC, mean (SD)4 85.2 (15.5) 90.3 (16.5)
ALSSQoL score, mean (SD)5 5.7 (0.7) 5.3 (0.9)
Use of riluzole, n (%) 27 (77) 58 (81)
ALS, amyotrophic lateral sclerosis; ALSFRS-R, Revised Amyotrophic Lat-
eral Sclerosis Functional Rating Scale; ALSSQoL, ALS-specific quality of
life; FEV1, forced expiratory volume in 1 sec; FVC, forced vital capac-
ity; MRC, Medical Research Council; NI, neurophysiological index; SD,
standard deviation; SI, split-hand index.
1The intention-to-treat population included all randomised patients.
2n = 33 in the placebo group; n = 69 in the dimethyl fumarate
group.
3n = 34 in the placebo group; n = 71 in the dimethyl fumarate
group.
4FVC is FEV1/FVC (actual percentage).
5n = 30 in the placebo group; n = 72 in the dimethyl fumarate
group.
Table 2. Least squares mean change from baseline in primary and






















































Urinary neurotrophin-receptor p75 level (ng/mg creatinine)5









ALSSQoL, amyotrophic lateral sclerosis-specific quality of life; CI, confi-
dence interval; FVC, forced vital capacity; LSM, least squares mean;
MRC, Medical Research Council; NI, neurophysiological index; SE, stan-
dard error; SI, split-hand index; SNIP, sniff nasal inspiratory pressure.
1The intention-to-treat population included all randomised patients.
Multiple imputation method was used for missing data. The intention-
to-treat population comprised 107 patients (72 patients in the
dimethyl fumarate group; 35 patients in the placebo group).
2n = number of patients evaluable for analysis through to week 36.
3ΔLSM = between-treatment-arm difference of LSM; 95% one-sided CIs.
4p ≤ 0.05, indicates statistically significant difference between placebo
and dimethyl fumarate.
5Primary endpoint.
6Secondary endpoint. ALSFRS-R, Revised Amyotrophic Lateral Sclerosis
Functional Rating Scale.
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week 12 in 15.9% participants (13.9% dimethyl fumarate,
20% placebo) and from week 24 in 12.1% of participants
(11.1% dimethyl fumarate, 14.3% placebo).
Additionally, there were no significant effects observed
in other secondary endpoints, including SI, MRC scores,
respiratory function, and quality of life scores (Table 2)
at week 36. In addition, urinary neurotrophin-receptor
p75 levels were comparable between the dimethyl fuma-
rate and placebo groups at week 36 (p = 0.27, Table 2).
Dimethyl fumarate did not demonstrate any beneficial
effect on survival compared with placebo (p = 0.09; haz-
ard ratio >99), with the majority of participants in the
dimethyl fumarate group (93.8%) and all in the placebo
group being censored.
In total, 86.0% of participants experienced at least one
adverse event during the study (dimethyl fumarate:
90.3%; placebo: 77.1%; p = 0.08, Table 3). Most adverse
reactions were mild and included cutaneous flushes, uri-
nary tract infection and upper respiratory tract infection
in the study population (Table 3). Treatment related
adverse events (TEAEs), namely cutaneous flushing, was
significantly more common in the dimethyl fumarate
group and is in keeping with expectations. Serious
adverse events were reported in 18.7% of participants
(19.4% in dimethyl fumarate group and 17.1% in placebo
group, Table 3). The serious adverse events were not
related to the study treatment. It should be stressed that
there were no significant differences between treatment
groups for the incidence of serious TEAEs, TEAEs leading
to permanent or temporary study drug discontinuation,
TEAEs leading to death and unexpected TEAEs.
Six participants (5.6%) discontinued the study because
of adverse events, five in dimethyl fumarate and 1 in pla-
cebo group. The most common adverse events resulting
in treatment were nausea (one patient in each group) and
abdominal pain (one patient each group). One patient
died during the study (in active group), and this was
related to (disease progression and unrelated to study
drug). Analyses of laboratory data, vital signs, and physi-
cal findings did not reveal clinically relevant changes in
either group throughout the study duration.
Discussion
Dimethyl fumarate was proposed as a possible disease-
modifying drug in ALS, acting via modulation of regulatory
T cell function, which has previously been shown to be
associated with a reduced rate of disease progression.17
Although the co-administration of dimethyl fumarate with
riluzole was found to be safe and well-tolerated in sporadic
ALS there was no significant difference between dimethyl
fumarate and placebo in the primary endpoint, namely
ALSFRS-R score, at week 36. There was no significant dif-
ference between dimethyl fumarate and placebo in sec-
ondary endpoints, including NI, survival and respiratory

























   
   
   
   
   









Figure 2. Least-squares mean change from baseline in ALSFRS-R at week 36 (last observation carried forward;* intention-to-treat population†).
Multiple imputation method = method of imputation for missing data; p ≤ 0.05 indicates statistically significant difference between groups.
†Intention-to-treat population included all randomised patients. ‡Placebo: n = 25 at week 36. §Dimethyl fumarate: n = 46 at week 36. ALSFRS-
R = Revised Amyotrophic Lateral Sclerosis Functional Rating Scale. CI = confidence interval. ΔLSM = least-squares mean difference (placebo vs.
dimethyl fumarate).
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controlled trial established the safety and tolerability of
dimethyl fumarate in sporadic ALS, with a beneficial effect
on NI, suggesting preservation of lower motor neuron
function, although this needs verification in a larger trial.
Dimethyl fumarate is a repurposed oral immunomodu-
latory agent, used in the treatment of relapsing-remitting
multiple sclerosis. It exerts anti-inflammatory and anti-
oxidant effects by binding to the transcription factor
nuclear factor erythroid-derived 2-like 2 (Nrf2).30 Specifi-
cally, dimethyl fumarate was shown to exhibit a relative
increase in Tregs and suppress cytotoxic (Th1/Th17) cells
as well. In addition, dimethyl fumarate switches the
molecular and functional phenotype of activated micro-
glia from the pro-inflammatory to anti-inflammatory
type, exerting neuroprotective effects.30 The preclinical
and clinical effects of dimethyl fumarate formed a scien-
tific rationale for assessing the potential clinical effective-
ness of dimethyl fumarate in our ALS cohort.
The primary endpoint (ALSFRS-R) was not signifi-
cantly different between dimethyl fumarate and placebo
groups, thereby arguing against the clinical effectiveness
of dimethyl fumarate in sporadic ALS. Additionally, the
rate of decline in NI was less in the treated cohort,
although this difference was not significant when imple-
menting the multiple imputation method. The NI is a
simple, reproducible and robust biomarker of lower
motor neuron dysfunction and disease progression in
ALS,28,29,31 and consequently would have utility in Phase
2 trials. It should be stressed that the present trial did not
prespecify power calculations according to changes in NI.
Future phase 2 trials could pre-specify NI as an outcome
biomarker to determine efficiency of compound at an
early stage of their development.
It should also be highlighted that the rate of decline in
the ALSFRS-R score over 36 weeks was unexpectedly
small, with a 5.66-point decline in the dimethyl fumarate
group and a 4.24-point decline in the placebo group.
Importantly, the decline in the ALSFRS-R was smaller
when compared with recent ALS clinical trials reporting
significant differences in the primary endpoints. Specifi-
cally, the calculated projected decline in ALSFRS-R at
week 36 in the edaravone trial (MCI-186) was 7.52 (ac-
tive)/11.25 (placebo),8 in the masitinib trial, the decline
was 6.93 (active)/9.47 (placebo),9 and in the CENTAUR
trial (Sodium Phenylbutyrate-Taurursodiol), the calcu-
lated decline was 11.16 (active)/14.94 (placebo),10 all
being higher than the current trial. The previous trials
selected for the “fast-ALS progressors,” which the present
study did not, could explain the absence of clinical signif-
icance and lower rates of ALSFRS-R decline in the current
trial. Future clinical trials should assess dimethyl fumarate
efficacy in “fast progressing” ALS patients.
Limitations
A potential limitation of the current trial relates to
immunotyping of the ALS patients during treatment.




(n = 72) (n = 35) (N = 107)
n (%) n (%) n (%)
Any adverse events, n (%) 65 (90.3) 27
(77.1)
92 (86.0)
Hot flushes 24 (33.3) 2 (5.7) 26 (24.3)
Urinary tract infection 6 (8.3) 6 (17.1) 12 (11.2)
Upper respiratory tract
infection
9 (12.5) 2 (5.7) 11 (10.3)
Flushing 9 (12.5) 1 (2.9) 10 (9.3)
Diarrhoea 6 (8.3) 2 (5.7) 8 (7.5)
Nausea 6 (8.3) 2 (5.7) 8 (7.5)
Abdominal pain 5 (6.9) 3 (8.6) 8 (7.5)
Constipation 4 (5.6) 2 (5.7) 6 (5.6)
Lymphopenia 5 (6.9) 0 5 (4.7)
Nasopharyngitis 4 (5.6) 0 4 (3.7)
Gastroenteritis 0 2 (5.7) 2 (1.9)
Back pain 0 2 (5.7) 2 (1.9)
Bursitis 0 2 (5.7) 2 (1.9)
Diverticulitis 0 1 (2.9) 1 (0.9)
Serious adverse events,
n (%)
14 (19.4) 6 (17.1) 20 (18.7)
Myocardial infarction 1 (1.4) 0 1 (0.9)
Abdominal pain 0 1 (2.9) 1 (0.9)
Colitis 1 (1.4) 0 1 (0.9)
Nausea 0 1 (2.9) 1 (0.9)
Oesophageal spasm 1 (1.4) 0 1 (0.9)
Small intestinal
obstruction
0 1 (2.9) 1 (0.9)
Non-cardiac chest pain 1 (1.4) 0 1 (0.9)
Diverticulitis 0 1 (2.9) 1 (0.9)
Lower respiratory tract
infection
1 (1.4) 0 1 (0.9)
Pneumonia 1 (1.4) 0 1 (0.9)
Pyelonephritis 0 1 (2.9) 1 (0.9)
Sinusitis 1 (1.4) 0 1 (0.9)
Head injury 1 (1.4) 0 1 (0.9)
Procedural pain 1 (1.4) 0 1 (0.9)
Arthralgia 1 (1.4) 0 1 (0.9)
Back pain 0 1 (2.9) 1 (0.9)
Squamous cell carcinoma 1 (1.4) 0 1 (0.9)
Pulmonary embolism 1 (1.4) 1 (2.9) 2 (1.9)
Pneumonia aspiration 1 (1.4) 0 1 (0.9)
Respiratory failure 1 (1.4) 0 1 (0.9)
Deep vein thrombosis 1 (1.4) 1 (2.9) 2 (1.9)
1Medical Dictionary for Regulatory Activities (MedDRA), Version 21.0,
used to code adverse events.
2Safety population included patients who were randomised and had
received at least one dose of the investigational drug.
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Specifically, T-cell profiling was not undertaken and con-
sequently, the absence of clinical effectiveness could have
been related to the failure of modulating effects of
dimethyl fumarate on T cell populations in the current
ALS cohort. Future studies should stratify patients based
on T cell profiles to determine whether dimethyl fumarate
could be more effective in participants exhibiting a
greater imbalance between the cytotoxic and helper T
cells. In addition, monitoring the biological effects of
dimethyl fumarate on T cell populations may help iden-
tify a responding cohort of ALS patients. Separately, it
could be argued that the higher-than-expected discontin-
uation rate influenced the results of the TEALS study.
This seems unlikely as the power calculations indicated
that 72 participants were required and a total of 107 par-
ticipants were randomised of which 75 completed the
study, thereby ensuring adequate study power.
Conclusion
In conclusion, the TEALS study established that dimethyl
fumarate was safe and well-tolerated in sporadic ALS par-
ticipants. There were no significant effects of dimethyl
fumarate on primary and secondary endpoints. Conse-
quently, the present trial provides class I evidence for
safety and lack of efficacy of dimethyl fumarate in ALS.
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